FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205113096> ?p ?o ?g. }

• W4205113096 abstract "The aftermath of the Covid-19 pandemic calls for a rethink of pharmaceutical options for treatment of viral respiratory infections. Respiratory infections start primarily at the surface epithelial cells. Being in permanent direct contact with the ambient air, the respiratory system tissue surface may be amenable to topical treatment approaches. We evaluate and define the method and options of translating effective wound care treatments into the realm of respiratory infections treatment and preventions. The goal is a broad-range, safe and cheap anti-viral respiratory infections medication, which can be made globally available for early-stage home use. In a previous publication we discussed nanoparticles-based formulations. In this article we propose and evaluate a new mode of use of a well-established topical antiseptic – PVP Iodine (PVP-I). In contrast to all previous proposals of PVP-I disinfection nasal sprays or oral gargle, we present a deep and well controlled inhalation protocol to disinfect in one treatment modality both the bronchial tree, upper respiratory nasal and throat tissue simultaneously, using ultrasonic mesh nebulizers. Molecular iodine is quickly absorbed from the lungs and bronchial tree into the blood, within about 10 minutes. Yet, iodine effectively disinfects most viruses within 1 minute, including SARS-CoV-2. Moreover, the slower to absorb PVP-I complex provides a continuously eluting reservoir that maintains the iodine concentration in the airways surface fluids for several hours. These and other factors unique to inhalation are discussed. We provide: (i) Dosage calculation and delivery protocols; (ii) Safety analysis based on guidelines, animal trials and WHO review reports; (iii) Evaluating published pilot clinical trials of SARS-CoV-2 with related nasal spray or oral gargle PVP-I treatments; (iv) Evaluating the potential use and modification of existing off-the-shelf market products to render our proposed treatment immediately available on a global scale. Our recommended formulations comprise of PVP-I at concentrations 0.5% - 5% and pH between pH=6.5 to pH=7.5 (significantly higher than pH~3.5 of present market products). Inhalation dosage of just 0.5 mL may already be effective, which translates to aerosolizing 2 mL with a common nebulizer device. PVP-I is globally available over the counter (OTC). The same is true of ultrasonic nebulizers. In practice, all the ingredients are already globally available to consumers. Hence, we hope health and regulatory authorities worldwide will invest the efforts to establish the validity of the proposed treatment. In the meantime, to prevent confusion or misuse by free-willing users and to facilitate clinical evaluation, we outline a prescription for the proper adaptation use of common commercially available market products. I addition, we propose that the same formulations and protocols can be implemented prophylactically in hospital intensive care units (ICU) for the prevention of ventilator associated pneumonia (VAP)." @default.
• W4205113096 created "2022-01-25" @default.
• W4205113096 creator A5067546003 @default.
• W4205113096 date "2021-05-29" @default.
• W4205113096 modified "2023-09-26" @default.
• W4205113096 title "Inhalation Formulation & Dosage of PVP Iodine for Respiratory Infections Treatment" @default.
• W4205113096 doi "https://doi.org/10.31219/osf.io/ns3yc" @default.
• W4205113096 hasPublicationYear "2021" @default.
• W4205113096 type Work @default.
• W4205113096 citedByCount "0" @default.
• W4205113096 crossrefType "posted-content" @default.
• W4205113096 hasAuthorship W4205113096A5067546003 @default.
• W4205113096 hasBestOaLocation W42051130961 @default.
• W4205113096 hasConcept C126322002 @default.
• W4205113096 hasConcept C142724271 @default.
• W4205113096 hasConcept C178790620 @default.
• W4205113096 hasConcept C185592680 @default.
• W4205113096 hasConcept C2776954882 @default.
• W4205113096 hasConcept C2781460226 @default.
• W4205113096 hasConcept C42219234 @default.
• W4205113096 hasConcept C534529494 @default.
• W4205113096 hasConcept C539932907 @default.
• W4205113096 hasConcept C71924100 @default.
• W4205113096 hasConcept C98274493 @default.
• W4205113096 hasConceptScore W4205113096C126322002 @default.
• W4205113096 hasConceptScore W4205113096C142724271 @default.
• W4205113096 hasConceptScore W4205113096C178790620 @default.
• W4205113096 hasConceptScore W4205113096C185592680 @default.
• W4205113096 hasConceptScore W4205113096C2776954882 @default.
• W4205113096 hasConceptScore W4205113096C2781460226 @default.
• W4205113096 hasConceptScore W4205113096C42219234 @default.
• W4205113096 hasConceptScore W4205113096C534529494 @default.
• W4205113096 hasConceptScore W4205113096C539932907 @default.
• W4205113096 hasConceptScore W4205113096C71924100 @default.
• W4205113096 hasConceptScore W4205113096C98274493 @default.
• W4205113096 hasLocation W42051130961 @default.
• W4205113096 hasOpenAccess W4205113096 @default.
• W4205113096 hasPrimaryLocation W42051130961 @default.
• W4205113096 hasRelatedWork W1455331800 @default.
• W4205113096 hasRelatedWork W1971257060 @default.
• W4205113096 hasRelatedWork W1986764680 @default.
• W4205113096 hasRelatedWork W2401352634 @default.
• W4205113096 hasRelatedWork W2417623367 @default.
• W4205113096 hasRelatedWork W2469966616 @default.
• W4205113096 hasRelatedWork W2549135832 @default.
• W4205113096 hasRelatedWork W2792454111 @default.
• W4205113096 hasRelatedWork W3158883658 @default.
• W4205113096 hasRelatedWork W4253600551 @default.
• W4205113096 isParatext "false" @default.
• W4205113096 isRetracted "false" @default.
• W4205113096 workType "article" @default.